OMERS ADMINISTRATION Corp Purchases New Position in Stoke Therapeutics, Inc. $STOK

OMERS ADMINISTRATION Corp purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,000 shares of the company’s stock, valued at approximately $982,000.

Several other hedge funds have also bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $26,000. Quantbot Technologies LP acquired a new stake in Stoke Therapeutics during the second quarter valued at $34,000. KBC Group NV purchased a new position in Stoke Therapeutics in the first quarter valued at $36,000. Harbour Investments Inc. increased its holdings in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares in the last quarter.

Stoke Therapeutics Stock Down 1.5%

STOK opened at $32.59 on Friday. The company has a market cap of $2.10 billion, a PE ratio of -9.76 and a beta of 1.20. Stoke Therapeutics, Inc. has a twelve month low of $18.80 and a twelve month high of $40.22. The company has a 50-day moving average price of $31.21 and a 200 day moving average price of $32.26.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The firm had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. As a group, sell-side analysts expect that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on STOK shares. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. The Goldman Sachs Group began coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price target for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group dropped their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.25.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 12,567 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares in the company, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 4,767 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $152,687.01. Following the completion of the transaction, the insider directly owned 25,655 shares of the company’s stock, valued at approximately $821,729.65. This represents a 15.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 30,623 shares of company stock valued at $953,765 over the last ninety days. Insiders own 9.60% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.